

# Attenuated replication and pathogenicity of SARS-CoV

Nature

603, 693-699

DOI: [10.1038/s41586-022-04442-5](https://doi.org/10.1038/s41586-022-04442-5)

Citation Report

#	ARTICLE	IF	CITATIONS
4	Editorial: The 2022 World Health Organization (WHO) Priority Recommendations and Response to the Omicron Variant (B.1.1.529) of SARS-CoV-2. <i>Medical Science Monitor</i> , 2022, 28, e936199.	0.5	14
5	Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. <i>Nature</i> , 2022, 603, 706-714.	13.7	756
6	Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic. <i>Environmental Research</i> , 2022, 209, 112816.	3.7	189
8	SARS-CoV-2 accessory protein ORF8 is secreted extracellularly as a glycoprotein homodimer. <i>Journal of Biological Chemistry</i> , 2022, 298, 101724.	1.6	28
10	An innovative two-wing model for balancing the demands of inpatients with COVID-19 and general medical service in a designated hospital for COVID-19 in Shenzhen, China. <i>BioScience Trends</i> , 2022, 16, 163-166.	1.1	3
11	Why Does the Omicron Variant Largely Spare Olfactory Function? Implications for the Pathogenesis of Anosmia in Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2022, 226, 1304-1308.	1.9	47
13	Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1987.	1.8	48
15	Successive Pandemic Waves with Different Virulent Strains and the Effects of Vaccination for SARS-CoV-2. <i>Vaccines</i> , 2022, 10, 343.	2.1	4
16	Isolation and Genomic Characterization of SARS-CoV-2 Omicron Variant Obtained from Human Clinical Specimens. <i>Viruses</i> , 2022, 14, 461.	1.5	9
19	High amounts of SARS-CoV-2 in aerosols exhaled by patients with Omicron variant infection. <i>Journal of Infection</i> , 2022, 84, e126-e128.	1.7	27
21	Fatal Neurodissemination and SARS-CoV-2 Tropism in K18-hACE2 Mice Is Only Partially Dependent on hACE2 Expression. <i>Viruses</i> , 2022, 14, 535.	1.5	47
22	Nonself Mutations in the Spike Protein Suggest an Increase in the Antigenicity and a Decrease in the Virulence of the Omicron Variant of SARS-CoV-2. <i>Covid</i> , 2022, 2, 407-418.	0.7	3
24	Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice. <i>Cell</i> , 2022, 185, 1572-1587.e11.	13.5	71
25	Coronavirus Vaccination and Mortality in the Omicron Outbreak in Iran: Mortality Reduction due to Attenuated Pathogenicity and Booster Vaccine Doses. <i>Avicenna Journal of Medical Biotechnology</i> , 0, , .	0.2	2
27	Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Subvariant BA.2 in a Single-Source Community Outbreak. <i>Clinical Infectious Diseases</i> , 2022, 75, e44-e49.	2.9	66
29	Global trends in COVID-19. , 2022, 1, 31-39.		8
30	Transmissibility and pathogenicity of SARS-CoV-2 variants in animal models. <i>Journal of Microbiology</i> , 2022, 60, 255-267.	1.3	9
34	Animal models in SARS-CoV-2 research. <i>Nature Methods</i> , 2022, 19, 392-394.	9.0	51

#	ARTICLE	IF	CITATIONS
35	Characteristic analysis of Omicronâ€included SARSâ€CoVâ€2 variants of concern. MedComm, 2022, 3, e129.	3.1	3
36	Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cellâ€cell fusion, and neutralization sensitivity. Emerging Microbes and Infections, 2022, 11, 1024-1036.	3.0	5
38	Strategies and safety considerations of booster vaccination in COVID-19. Bosnian Journal of Basic Medical Sciences, 2022, , .	0.6	5
39	Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters. Med, 2022, 3, 262-268.e4.	2.2	117
40	Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern. EBioMedicine, 2022, 79, 103997.	2.7	29
42	Structures of Omicron spike complexes and implications for neutralizing antibody development. Cell Reports, 2022, 39, 110770.	2.9	47
44	Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. Human Vaccines and Immunotherapeutics, 2022, 18, 1-12.	1.4	10
45	Comparison of Vaccine Effectiveness Against the Omicron (B.1.1.529) Variant in Hemodialysis Patients. Kidney International Reports, 2022, 7, 1406-1409.	0.4	26
46	COVID-19 and tuberculosis: the double whammy of respiratory pathogens. European Respiratory Review, 2022, 31, 210264.	3.0	40
47	Structural and functional impact by SARS-CoV-2 Omicron spike mutations. Cell Reports, 2022, 39, 110729.	2.9	102
48	COVIDâ€19: Omicron â€ the latest, the least virulent, but probably not the last variant of concern of SARSâ€CoVâ€2. Microbial Biotechnology, 2022, 15, 1927-1939.	2.0	41
49	SARS-CoV-2 Infection: Host Response, Immunity, and Therapeutic Targets. Inflammation, 2022, 45, 1430-1449.	1.7	16
50	Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study. Lancet Infectious Diseases, The, 2022, 22, 967-976.	4.6	140
51	Omicron BA.2 (B.1.1.529.2): High Potential for Becoming the Next Dominant Variant. Journal of Physical Chemistry Letters, 2022, 13, 3840-3849.	2.1	79
52	Bacillus Calmette-GuÃ©rinâ€induced trained immunity protects against SARS-CoV-2 challenge in K18-hACE2 mice. JCI Insight, 2022, 7, .	2.3	29
54	Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. BioDrugs, 2022, 36, 231-323.	2.2	24
56	Replication kinetics and infectivity of SARS-CoV-2 variants of concern in common cell culture models. Virology Journal, 2022, 19, 76.	1.4	61
58	New endemic and pandemic pathologies with interhuman airborne transmission through ear, nose and throat anatomical sites. Acta Otorhinolaryngologica Italica, 2022, 42, S5-S13.	0.7	6

#	ARTICLE	IF	CITATIONS
59	SARS-CoV-2 Omicron variant: recent progress and future perspectives. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 141.	7.1	315
60	An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron. <i>Nature Microbiology</i> , 2022, 7, 716-725.	5.9	62
61	Application of animal models to compare and contrast the virulence of current and future potential SARS-CoV-2 variants. <i>Biosafety and Health</i> , 2022, 4, 154-160.	1.2	3
62	Re: Vertical transmission and humoral immune response following maternal infection with SARS-CoV-2 by Massalha etÂal.. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1400.	2.8	1
63	Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike. <i>Cell</i> , 2022, 185, 2103-2115.e19.	13.5	273
64	The Reassessed Potential of SARS-CoV-2 Attenuation for COVID-19 Vaccine Developmentâ€”A Systematic Review. <i>Viruses</i> , 2022, 14, 991.	1.5	10
65	Emerging SARS-CoV-2 variants: Why, how, and what's next?., 2022, 1, 100029.		26
66	Pathogenicity of SARSâ€CoVâ€2 Omicron. <i>Clinical and Translational Medicine</i> , 2022, 12, e880.	1.7	12
67	Clinical Characteristics of COVID-19 Patients Infected by the Omicron Variant of SARS-CoV-2. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	39
68	Pathogenicity of SARS-CoV-2 Omicron BA.1.1 in hamsters. <i>EBioMedicine</i> , 2022, 80, 104035.	2.7	4
69	Why is the SARS-CoV-2 Omicron variant milder?. <i>Innovation(China)</i> , 2022, 3, 100251.	5.2	12
70	Equipment-free, gold nanoparticle based semiquantitative assay of SARS-CoV-2-S1RBD IgG from fingertip blood: A practical strategy for on-site measurement of COVID-19 antibodies. <i>Talanta</i> , 2022, 246, 123498.	2.9	3
71	Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants. <i>Nature Communications</i> , 2022, 13, 2674.	5.8	26
72	Many Keys Unlock the Doors for Virus Entry. <i>MBio</i> , 2022, , e0044522.	1.8	0
73	Being a Public Health Statistician During a Global Pandemic. <i>Statistical Science</i> , 2022, 37, .	1.6	4
74	Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. <i>Nature</i> , 2022, 607, 119-127.	13.7	174
75	Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination. <i>Nature</i> , 2022, 607, 351-355.	13.7	143
79	The putative mechanism of lymphopenia in COVID-19 patients. <i>Journal of Molecular Cell Biology</i> , 2022, 14, .	1.5	5

#	ARTICLE	IF	CITATIONS
81	High Level of SARS-CoV-2 Infection in Young Population Is a Predictor for Peak Incidence. <i>Frontiers in Microbiology</i> , 2022, 13, .	1.5	1
82	Differential Pathogenesis of SARS-CoV-2 Variants of Concern in Human ACE2-Expressing Mice. <i>Viruses</i> , 2022, 14, 1139.	1.5	21
83	Impact of SARS-CoV-2 infection on liver disease. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2022, 3, 126-133.	0.1	0
85	Recent insights into SARS-CoV-2 omicron variant. <i>Reviews in Medical Virology</i> , 2023, 33, .	3.9	29
86	Infección por SARS-CoV-2 y su impacto en la enfermedad hepática. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2022, 3, 134-141.	0.1	0
87	Application of exosomes for the alleviation of COVID-19-related pathologies. <i>Cell Biochemistry and Function</i> , 2022, 40, 430-438.	1.4	7
88	Estimating relative generation times and reproduction numbers of Omicron BA.1 and BA.2 with respect to Delta variant in Denmark. <i>Mathematical Biosciences and Engineering</i> , 2022, 19, 9005-9017.	1.0	32
90	Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant. <i>Clinical Microbiology Reviews</i> , 2022, 35, .	5.7	35
91	SARS-CoV-2: A Master of Immune Evasion. <i>Biomedicines</i> , 2022, 10, 1339.	1.4	24
92	Omicron Spike Protein Has a Positive Electrostatic Surface That Promotes ACE2 Recognition and Antibody Escape. <i>Frontiers in Virology</i> , 0, 2, .	0.7	33
93	The Potential of Purinergic Signaling to Thwart Viruses Including SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
94	Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	33
95	Dual Inhibition of Vacuolar-ATPase and TMPRSS2 Is Required for Complete Blockade of SARS-CoV-2 Entry into Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	20
96	Inhibitors of Activin Receptor-like Kinase 5 Interfere with SARS-CoV-2 S-Protein Processing and Spike-Mediated Cell Fusion via Attenuation of Furin Expression. <i>Viruses</i> , 2022, 14, 1308.	1.5	1
97	Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters. <i>Science</i> , 2022, 377, 428-433.	6.0	113
98	The Ecology of Viral Emergence. <i>Annual Review of Virology</i> , 2022, 9, 173-192.	3.0	20
100	Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants. <i>Viruses</i> , 2022, 14, 1255.	1.5	30
101	SARS-CoV-2 Omicron BA.5: Evolving Tropism and Evasion of Potent Humoral Responses and Resistance to Clinical Immunotherapeutics Relative to Viral Variants of Concern. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3

#	ARTICLE	IF	CITATIONS
102	Ongoing Positive Selection Drives the Evolution of SARS-CoV-2 Genomes. <i>Genomics, Proteomics and Bioinformatics</i> , 2022, 20, 1214-1223.	3.0	9
103	K18- and CAG-hACE2 Transgenic Mouse Models and SARS-CoV-2: Implications for Neurodegeneration Research. <i>Molecules</i> , 2022, 27, 4142.	1.7	7
104	The nervous system during COVID-19: Caught in the crossfire. <i>Immunological Reviews</i> , 2022, 311, 90-111.	2.8	9
105	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	59
106	Sequencing during Times of Change: Evaluating SARS-CoV-2 Clinical Samples during the Transition from the Delta to Omicron Wave. <i>Viruses</i> , 2022, 14, 1408.	1.5	3
107	Periodontitis and COVID-19: Biological Mechanisms and Meta-analyses of Epidemiological Evidence. <i>Journal of Dental Research</i> , 2022, 101, 1430-1440.	2.5	30
108	Clinical Characteristics of Omicron SARS-CoV-2 Variant Infection After Non-mRNA-Based Vaccination in China. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	8
109	Considering innate immune responses in SARS-CoV-2 infection and COVID-19. <i>Nature Reviews Immunology</i> , 2022, 22, 465-470.	10.6	14
110	Global Trends in Nursing-Related Research on COVID-19: A Bibliometric Analysis. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	11
111	A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron. <i>Communications Biology</i> , 2022, 5, .	2.0	26
112	Predictive Risk Factors at Admission and a "Burning Point" During Hospitalization Serve as Sequential Alerts for Critical Illness in Patients With COVID-19. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
113	COVID-19-Associated Lung Fibrosis: Two Pathways and Two Phenotypes, Lung Transplantation, and Antifibrotics. <i>Transplantation</i> , 2022, 3, 230-240.	0.3	1
114	A booster dose of Delta-Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	42
116	Reduced Pathogenicity and Transmission Potential of Omicron BA.1 and BA.2 Sublineages Compared with the Early Severe Acute Respiratory Syndrome Coronavirus 2 D614G Variant in Syrian Hamsters. <i>Journal of Infectious Diseases</i> , 2023, 227, 1143-1152.	1.9	16
117	SARS-CoV-2 Omicron: a new challenge for pandemic and vaccine. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	4
118	Importance score of SARS-CoV-2 genome predicts the death risk of COVID-19. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	2
119	Molecular dynamics studies reveal structural and functional features of the SARS-CoV-2 spike protein. <i>BioEssays</i> , 2022, 44, .	1.2	9
121	Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities. <i>Science Advances</i> , 2022, 8, .	4.7	27

#	ARTICLE	IF	CITATIONS
122	Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies. <i>EBioMedicine</i> , 2022, 82, 104158.	2.7	128
123	Alveolar macrophages: Achillesâ€™ heel of SARS-CoV-2 infection. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	15
124	SARS-CoV-2â€™s Variants of Concern: A Brief Characterization. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	31
125	SARS-CoV-2 Intermittent Virulence as a Result of Natural Selection. <i>Covid</i> , 2022, 2, 1089-1101.	0.7	1
126	The First Identification in Italy of SARS-CoV-2 Omicron BA.4 Harboring KSF141_del: A Genomic Comparison with Omicron Sub-Variants. <i>Biomedicines</i> , 2022, 10, 1839.	1.4	3
129	Evolution of ACE2-independent SARS-CoV-2 infection and mouse adaption after passage in cells expressing human and mouse ACE2. <i>Virus Evolution</i> , 2022, 8, .	2.2	14
132	Subâ€™lineages of the SARSâ€™CoVâ€™2 Omicron variants:â€™Characteristics and prevention. <i>MedComm</i> , 2022, 3, .	3.1	15
133	Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants. <i>Journal of Virology</i> , 2022, 96, .	1.5	12
134	Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). <i>Emerging Microbes and Infections</i> , 2022, 11, 2315-2325.	3.0	3
136	The Omicron Variant BA.1.1 Presents a Lower Pathogenicity than B.1 D614G and Delta Variants in a Feline Model of SARS-CoV-2 Infection. <i>Journal of Virology</i> , 2022, 96, .	1.5	35
137	Coronaviruses exploit a host cysteine-aspartic protease for replication. <i>Nature</i> , 0, , .	13.7	19
138	The spike receptor-binding motif G496S substitution determines the replication fitness of SARS-CoV-2 Omicron sublineage. <i>Emerging Microbes and Infections</i> , 2022, 11, 2093-2101.	3.0	5
139	Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113522.	2.5	56
140	Spike mutation resilient scFv76 antibody counteracts SARS-CoV-2 lung damage upon aerosol delivery. <i>Molecular Therapy</i> , 2023, 31, 362-373.	3.7	0
142	SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. <i>EBioMedicine</i> , 2022, 84, 104270.	2.7	86
143	The mechanisms of immune response and evasion by the main SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 105044.	1.9	8
144	Wastewater to clinical case (WC) ratio of COVID-19 identifies insufficient clinical testing, onset of new variants of concern and population immunity in urban communities. <i>Science of the Total Environment</i> , 2022, 853, 158547.	3.9	19
145	Targeting ACLY efficiently inhibits SARS-CoV-2 replication. <i>International Journal of Biological Sciences</i> , 2022, 18, 4714-4730.	2.6	4

#	ARTICLE	IF	CITATIONS
146	Cross-variant protection against SARS-CoV-2 infection in hamsters immunized with monovalent and bivalent inactivated vaccines. <i>International Journal of Biological Sciences</i> , 2022, 18, 4781-4791.	2.6	5
147	Phosphatidic acid phosphatase 1 impairs SARS-CoV-2 replication by affecting the glycerophospholipid metabolism pathway. <i>International Journal of Biological Sciences</i> , 2022, 18, 4744-4755.	2.6	12
148	SARS-CoV-2 Vaccine Against Virus: Mission Accomplished!?. , 2022, , 561-574.		0
149	Prospects of Coffee Leaf against SARS-CoV-2 Infection. <i>International Journal of Biological Sciences</i> , 2022, 18, 4677-4689.	2.6	7
150	Home Isolation and Online Support Strategies to Mild COVID-19 Epidemic Waves in Thailand: Preparing for the Next. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
151	COVID-19 Infection: The Virus and Its Origin, the Variants, the Immune Defense, the Multiorgan Autoimmune Reactions, and the Targeted Treatments. <i>Advances in Infectious Diseases</i> , 2022, 12, 568-631.	0.0	1
152	Sports Participation and Anti-Epidemic: Empirical Evidence on the Influence of Regular Physical Activity on the COVID-19 Pandemic in Mainland China. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 10689.	1.2	1
153	Differences Between Omicron Infections and Fever Outpatients: Comparison of Clinical Manifestations and Initial Routine Hematology Indicators. <i>Infection and Drug Resistance</i> , 0, Volume 15, 5111-5120.	1.1	2
154	SARS-CoV-2 does not infect pigs, but this has to be verified regularly. <i>Xenotransplantation</i> , 2022, 29, .	1.6	3
156	A molecularly engineered, broad-spectrum anti-coronavirus lectin inhibits SARS-CoV-2 and MERS-CoV infection in vivo. <i>Cell Reports Medicine</i> , 2022, 3, 100774.	3.3	14
157	Rhabdomyolysis in Pediatric Patients with SARS-CoV-2 Infection. <i>Children</i> , 2022, 9, 1441.	0.6	4
158	A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant. <i>Nature Communications</i> , 2022, 13, .	5.8	37
159	Human ACE2 Peptide-Attached Plasmonic-Magnetic Heterostructure for Magnetic Separation, Surface Enhanced Raman Spectroscopy Identification, and Inhibition of Different Variants of SARS-CoV-2 Infections. <i>ACS Applied Bio Materials</i> , 2022, 5, 4454-4464.	2.3	4
160	Dual-Functional Anti-Pathogen Coatings. <i>Advanced Materials Interfaces</i> , 2022, 9, .	1.9	1
161	Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2. <i>Cell Reports Medicine</i> , 2022, 3, 100743.	3.3	19
162	Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	55
163	Characteristics of replication and pathogenicity of SARS-CoV-2 Alpha and Delta isolates. <i>Virologica Sinica</i> , 2022, 37, 804-812.	1.2	4
164	SARS-CoV-2 variants Alpha, Beta, Delta and Omicron show a slower host cell interferon response compared to an early pandemic variant. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7



#	ARTICLE	IF	CITATIONS
165	Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2. <i>Emerging Microbes and Infections</i> , 2022, 11, 2275-2287.	3.0	48
166	Spike protein-independent attenuation of SARS-CoV-2 Omicron variant in laboratory mice. <i>Cell Reports</i> , 2022, 40, 111359.	2.9	23
168	Real-life Evidence of Lower Lung Virulence in COVID-19 Inpatients Infected with SARS-CoV-2 Omicron Variant Compared to Wild-Type and Delta SARS-CoV-2 Pneumonia. <i>Lung</i> , 2022, 200, 573-577.	1.4	11
169	Scaling Biosafety Up During and Down After the COVID-19 Pandemic. <i>Applied Biosafety</i> , 2022, 27, 247-254.	0.2	1
170	Effect of Delta and Omicron Mutations on the RBD-SD1 Domain of the Spike Protein in SARS-CoV-2 and the Omicron Mutations on RBD-ACE2 Interface Complex. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10091.	1.8	8
171	An international observational study to assess the impact of the Omicron variant emergence on the clinical epidemiology of COVID-19 in hospitalised patients. <i>ELife</i> , 0, 11, .	2.8	8
175	The first case of meningitis associated with SARS-CoV-2 BA.2 variant infection with persistent viremia. <i>International Journal of Infectious Diseases</i> , 2022, 124, 38-40.	1.5	2
178	Introduction of graphene oxide-supported multilayer-quantum dots nanofilm into multiplex lateral flow immunoassay: A rapid and ultrasensitive point-of-care testing technique for multiple respiratory viruses. <i>Nano Research</i> , 2023, 16, 3063-3073.	5.8	17
179	SARS-CoV-2 Omicron variant is attenuated for replication in a polarized human lung epithelial cell model. <i>Communications Biology</i> , 2022, 5, .	2.0	34
180	Infection, pathology and interferon treatment of the SARS-CoV-2 Omicron BA.1 variant in juvenile, adult and aged Syrian hamsters. , 2022, 19, 1392-1399.		5
181	Neuropilin-1 Mediates SARS-CoV-2 Infection of Astrocytes in Brain Organoids, Inducing Inflammation Leading to Dysfunction and Death of Neurons. <i>MBio</i> , 2022, 13, .	1.8	33
182	The investigation of the complex population-drug-drug interaction between ritonavir-boosted lopinavir and chloroquine or ivermectin using physiologically-based pharmacokinetic modeling. <i>Drug Metabolism and Personalized Therapy</i> , 2022, .	0.3	4
183	SARS-CoV-2 Variant-Specific Infectivity and Immune Profiles Are Detectable in a Humanized Lung Mouse Model. <i>Viruses</i> , 2022, 14, 2272.	1.5	3
184	Systematic lung ultrasound in Omicron-type vs. wild-type COVID-19. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 24, 59-67.	0.5	2
186	Early pathogenesis profiles across SARS-CoV-2 variants in K18-hACE2 mice revealed differential triggers of lung damages. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
187	SARS-CoV-2 Variants Show a Gradual Declining Pathogenicity and Pro-Inflammatory Cytokine Stimulation, an Increasing Antigenic and Anti-Inflammatory Cytokine Induction, and Rising Structural Protein Instability: A Minimal Number Genome-Based Approach. <i>Inflammation</i> , 2023, 46, 297-312.	1.7	12
189	SARS-CoV-2 spike protein as a bacterial lipopolysaccharide delivery system in an overzealous inflammatory cascade. <i>Journal of Molecular Cell Biology</i> , 2023, 14, .	1.5	12
190	The Burden of Omicron Variant in Pakistan: An Updated Review. <i>Covid</i> , 2022, 2, 1460-1476.	0.7	1

#	ARTICLE	IF	CITATIONS
191	Omicron SARS-CoV-2 Spike-1 Protein's Decreased Binding Affinity to $\beta_7nAChR$ : Implications for Autonomic Dysregulation of the Parasympathetic Nervous System and the Cholinergic Anti-Inflammatory Pathway—An In Silico Analysis. <i>BioMedInformatics</i> , 2022, 2, 553-564.	1.0	2
192	Essential role of TMPRSS2 in SARS-CoV-2 infection in murine airways. <i>Nature Communications</i> , 2022, 13, .	5.8	46
193	Characteristics of animal models for COVID-19. <i>Animal Models and Experimental Medicine</i> , 2022, 5, 401-409.	1.3	7
194	Choosing a cellular model to study SARS-CoV-2. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	22
195	Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice. <i>Nature Medicine</i> , 2023, 29, 247-257.	15.2	98
196	Vimentin is an important ACE2 co-receptor for SARS-CoV-2 in epithelial cells. <i>IScience</i> , 2022, 25, 105463.	1.9	11
197	Comparison of SARS-CoV-2 Viral Loads in the Nasal Mucosa of Patients Infected With BA.1, BA.2, or BA.5 Omicron Lineages. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	2
198	A Pathway Model to Understand the Evolution of Spike Protein Binding to ACE2 in SARS-CoV-2 Variants. <i>Biomolecules</i> , 2022, 12, 1607.	1.8	1
199	Dynamic analysis and optimal control considering cross transmission and variation of information. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
200	Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents. <i>Nature</i> , 2022, 612, 540-545.	13.7	60
201	Aptamer-Gated Mesoporous Silica Nanoparticles for N Protein Triggered Release of Remdesivir and Treatment of Novel Coronavirus (2019-nCoV). <i>Biosensors</i> , 2022, 12, 950.	2.3	2
202	Nasal irrigation efficiently attenuates SARS-CoV-2 Omicron infection, transmission and lung injury in the Syrian hamster model. <i>IScience</i> , 2022, 25, 105475.	1.9	8
203	Changing trends of patient characteristics and treatment pathways during the COVID-19 pandemic: A cross-sectional analysis of 72,459 inpatient cases from the German Helios database. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	0
204	Human early syncytiotrophoblasts are highly susceptible to SARS-CoV-2 infection. <i>Cell Reports Medicine</i> , 2022, 3, 100849.	3.3	12
206	A review of COVID vaccines: success against a moving target. <i>British Medical Bulletin</i> , 2022, 144, 12-44.	2.7	5
207	Role of SARS-CoV-2-induced cytokine storm in multi-organ failure: Molecular pathways and potential therapeutic options. <i>International Immunopharmacology</i> , 2022, 113, 109428.	1.7	22
208	Hepatic dysfunctions in COVID-19 patients infected by the omicron variant of SARS-CoV-2. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
209	Association of Infection with Different SARS-CoV-2 Variants during Pregnancy with Maternal and Perinatal Outcomes: A Systematic Review and Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 15932.	1.2	17

#	ARTICLE	IF	CITATIONS
210	Advances in Next-Generation Coronavirus Vaccines in Response to Future Virus Evolution. <i>Vaccines</i> , 2022, 10, 2035.	2.1	3
211	Enhanced replication of SARS-CoV-2 Omicron BA.2 in human forebrain and midbrain organoids. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	13
212	Influence and Control of SARS-CoV-2 Transmission under Two Different Models. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 11849.	1.3	0
213	Identification of severe acute respiratory syndrome coronavirus 2 breakthrough infections by anti-nucleocapsid antibody among fully vaccinated non-healthcare workers during the transition from the delta to omicron wave. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
214	Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. <i>Cell Host and Microbe</i> , 2023, 31, 9-17.e3.	5.1	163
215	Replacement dynamics and the pathogenesis of the Alpha, Delta and Omicron variants of SARS-CoV-2. <i>Epidemiology and Infection</i> , 2023, 151, .	1.0	3
216	“Dynamic zero-COVID” policy and viral clearance during an omicron wave in Tianjin, China: a city-wide retrospective observational study. <i>BMJ Open</i> , 2022, 12, e066359.	0.8	8
217	Trends in Cases, Hospitalizations, and Mortality Related to the Omicron BA.4/BA.5 Subvariants in South Africa. <i>Clinical Infectious Diseases</i> , 2023, 76, 1468-1475.	2.9	15
218	Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses. <i>Nature Communications</i> , 2022, 13, .	5.8	17
220	What is the prevalence of COVID-19 detection by PCR among deceased individuals in Lusaka, Zambia? A postmortem surveillance study. <i>BMJ Open</i> , 2022, 12, e066763.	0.8	9
221	Reduced airborne transmission of SARS-CoV-2 BA.1 Omicron virus in Syrian hamsters. <i>PLoS Pathogens</i> , 2022, 18, e1010970.	2.1	13
222	Is the Stalk of the SARS-CoV-2 Spike Protein Druggable?. <i>Viruses</i> , 2022, 14, 2789.	1.5	0
223	Viral proteases as therapeutic targets. <i>Molecular Aspects of Medicine</i> , 2022, 88, 101159.	2.7	17
224	Viral dynamics during SARS-CoV-2 omicron infection highlight presymptomatic and asymptomatic infectiousness. <i>Journal of Infection</i> , 2022, , .	1.7	3
225	Use of remdesivir for COVID-19 in patients with hematologic cancer. <i>Clinical and Experimental Medicine</i> , 0, , .	1.9	2
226	The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages. <i>Virologica Sinica</i> , 2022, 37, 786-795.	1.2	12
227	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong. <i>The Lancet Regional Health - Western Pacific</i> , 2023, 32, 100660.	1.3	9
229	Neutralizing antibody titers to Omicron six months after vaccination with BNT162b2 in Colombia. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1

#	ARTICLE	IF	CITATIONS
230	Omicron-BA.1 Dispersion Rates in Mexico Varied According to the Regional Epidemic Patterns and the Diversity of Local Delta Subvariants. <i>Viruses</i> , 2023, 15, 243.	1.5	5
231	Baseline Sequencing Surveillance of Public Clinical Testing, Hospitals, and Community Wastewater Reveals Rapid Emergence of SARS-CoV-2 Omicron Variant of Concern in Arizona, USA. <i>MBio</i> , 2023, 14, .	1.8	5
232	Knowledge mapping of COVID-19 and dentistry: A bibliometric analysis. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
233	A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies. <i>Viruses</i> , 2023, 15, 167.	1.5	87
234	Spike and nsp6 are key determinants of SARS-CoV-2 Omicron BA.1 attenuation. <i>Nature</i> , 2023, 615, 143-150.	13.7	52
235	Gut Microbiota in Coronavirus Disease 2019. , 2023, , 289-302.		0
237	Pathophysiology of SARS-CoV-2 Infection of Nasal Respiratory and Olfactory Epithelia and Its Clinical Impact. <i>Current Allergy and Asthma Reports</i> , 2023, 23, 121-131.	2.4	6
238	A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model. <i>Journal of Virology</i> , 0, , .	1.5	2
239	Do SARS-CoV-2 Variants Differ in Their Neuropathogenicity?. <i>MBio</i> , 0, , .	1.8	1
240	SARS-CoV-2 variants induce distinct disease and impact in the bone marrow and thymus of mice. <i>IScience</i> , 2023, 26, 105972.	1.9	3
241	SARS-CoV-2 variant biology: immune escape, transmission and fitness. <i>Nature Reviews Microbiology</i> , 0, , .	13.6	160
242	A novel heterologous receptor-binding domain dodecamer universal mRNA vaccine against SARS-CoV-2 variants. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 4291-4304.	5.7	2
243	<i>H</i> LA-A*01:01 allele diminishing in COVID-19 patients population associated with non-structural epitope abundance in CD8+ T-cell repertoire. <i>PeerJ</i> , 0, 11, e14707.	0.9	1
244	T Cell Immune Responses against SARS-CoV-2 in the With Corona Era. <i>Biomedical Science Letters</i> , 2022, 28, 211-222.	0.0	0
245	A C57BL/6 Mouse Model of SARS-CoV-2 Infection Recapitulates Age- and Sex-Based Differences in Human COVID-19 Disease and Recovery. <i>Vaccines</i> , 2023, 11, 47.	2.1	6
246	Emerging Dominant SARS-CoV-2 Variants. <i>Journal of Chemical Information and Modeling</i> , 2023, 63, 335-342.	2.5	12
247	Links between COVID-19 and Parkinsonâ€™s disease/Alzheimerâ€™s disease: reciprocal impacts, medical care strategies and underlying mechanisms. <i>Translational Neurodegeneration</i> , 2023, 12, .	3.6	15
248	Altered host protease determinants for SARS-CoV-2 Omicron. <i>Science Advances</i> , 2023, 9, .	4.7	12

#	ARTICLE	IF	CITATIONS
249	SARS-CoV-2 and its impact on the cardiovascular and digestive systems – The interplay between new virus variants and human cells. <i>Computational and Structural Biotechnology Journal</i> , 2023, 21, 1022-1029.	1.9	2
250	SARS-CoV-2 evolution influences GBP and IFITM sensitivity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	12
252	SARS-CoV-2 Omicron (B.1.1.529) Variant: A Challenge with COVID-19. <i>Diagnostics</i> , 2023, 13, 559.	1.3	12
253	Differences in Presentation of SARS-CoV-2 Omicron Strain Variant BA.1 – BA.5 Peptides by HLA Molecules. <i>Doklady Biochemistry and Biophysics</i> , 2022, 507, 298-301.	0.3	2
255	Molecular recognition of SARS-CoV-2 spike protein with three essential partners: exploring possible immune escape mechanisms of viral mutants. <i>Journal of Molecular Modeling</i> , 2023, 29, .	0.8	4
256	The spread of the omicron variant: Identification of knowledge gaps, virus diffusion modelling, and future research needs. <i>Environmental Research</i> , 2023, 225, 115612.	3.7	7
257	Unveiling mutation effects on the structural dynamics of the main protease from SARS-CoV-2 with hybrid simulation methods. <i>Journal of Molecular Graphics and Modelling</i> , 2023, 121, 108443.	1.3	2
258	A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	20
259	Tight junction protein occludin is an internalization factor for SARS-CoV-2 infection and mediates virus cell-to-cell transmission. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	3
260	Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV). <i>European Journal of Medicinal Chemistry</i> , 2023, 254, 115376.	2.6	7
261	Cynomolgus Macaque Model for COVID-19 Delta Variant. <i>Immune Network</i> , 2022, 22, .	1.6	2
262	Cardiologic Manifestations in Omicron – Type Versus Wild – Type COVID – 19: A Systematic Echocardiographic Study. <i>Journal of the American Heart Association</i> , 2023, 12, .	1.6	5
263	Development of a novel mathematical model that explains SARS-CoV-2 infection dynamics in Caco-2 cells. <i>PeerJ</i> , 0, 11, e14828.	0.9	2
264	Clinical Outcomes of Omicron Variant (B.1.1.529) Infection in Children and Adolescents Hospitalized With COVID-19 in Brazil With Observational Data on the Efficacy of the Vaccines in Adolescents. <i>Pediatric Infectious Disease Journal</i> , 2023, 42, 218-225.	1.1	4
265	Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis. <i>Lancet, The</i> , 2023, 401, 664-672.	6.3	84
266	The risk of mortality and severe illness in patients infected with the omicron variant relative to delta variant of SARS-CoV-2: a systematic review and meta-analysis. <i>Irish Journal of Medical Science</i> , 2023, 192, 2897-2904.	0.8	2
268	Genomic Surveillance for SARS-CoV-2 – China, September 26, 2022 to January 29, 2023. <i>China CDC Weekly</i> , 2023, 5, 143-151.	1.0	14
269	The ambulatory care of patients with post-acute sequelae of COVID-19. , 2023, 2, .		1

#	ARTICLE	IF	CITATIONS
270	Surfing the Waves: Differences in Hospitalised COVID-19 Patients across 4 Variant Waves in a Belgian University Hospital. <i>Viruses</i> , 2023, 15, 618.	1.5	7
271	SARS-CoV-2/Omicron subvariants: global outbreak upsurge and expected upcoming threats. <i>International Journal of Surgery</i> , 2023, 109, 94-95.	1.1	0
272	Cycle threshold values are not associated with mortality: Risk factor analysis in older patients with the SARS-CoV-2 Omicron variant. <i>Travel Medicine and Infectious Disease</i> , 2023, 52, 102555.	1.5	0
273	COVID-19 mRNA vaccine protects against SARS-CoV-2 Omicron BA.1 infection in diet-induced obese mice through boosting host innate antiviral responses. <i>EBioMedicine</i> , 2023, 89, 104485.	2.7	4
274	Development of a screening platform to discover natural products active against SARS-CoV-2 infection using lung organoid models. <i>Biomaterials Research</i> , 2023, 27, .	3.2	9
275	Neuropathology of 30 deceased patients with COVID-19: a case series in Tehran, Iran. <i>Annals of Medicine and Surgery</i> , 2023, 85, 271-275.	0.5	0
276	Emergence of epidemic variants of SARS-CoV-2 by acquiring combinations of new highly mutable nucleotides in its genome. <i>Journal of Infection</i> , 2023, , .	1.7	0
277	Variants of SARS-CoV-2: Influences on the Vaccinesâ€™ Effectiveness and Possible Strategies to Overcome Their Consequences. <i>Medicina (Lithuania)</i> , 2023, 59, 507.	0.8	5
278	Intranasal Boosting with Spike Fc-RBD of Wild-Type SARS-CoV-2 Induces Neutralizing Antibodies against Omicron Subvariants and Reduces Viral Load in the Nasal Turbinate of Mice. <i>Viruses</i> , 2023, 15, 687.	1.5	4
279	Total and Subgenomic RNA Viral Load in Patients Infected With SARS-CoV-2 Alpha, Delta, and Omicron Variants. <i>Journal of Infectious Diseases</i> , 2023, 228, 235-244.	1.9	1
281	Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
283	Deep Structural Analysis of Myriads of Omicron Sub-Variants Revealed Hotspot for Vaccine Escape Immunity. <i>Vaccines</i> , 2023, 11, 668.	2.1	3
284	Interpretation of the Expert Consensus on the Traditional Chinese Medicine Prevention and Treatment of Coronavirus Disease 2019 Omicron Variant Infections. , 2022, 9, 13.		0
285	Clinical outcomes of the severe acute respiratory syndrome coronavirus 2 Omicron and Delta variant: systematic review and meta-analysis of 33 studies covering 6Â037Â144 coronavirus disease 2019â€™positive patients. <i>Clinical Microbiology and Infection</i> , 2023, 29, 835-844.	2.8	29
286	The shift of percent excess mortality from zero-COVID policy to living-with-COVID policy in Singapore, South Korea, Australia, New Zealand and Hong Kong SAR. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	3
287	Omicronâ€induced interferon signaling prevents influenza A H1N1 and H5N1 virus infection. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
288	Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization. <i>IScience</i> , 2023, 26, 106457.	1.9	3
289	Nirmatrelvir treatment of SARSâ€CoVâ€infectd mice blunts antiviral adaptive immune responses. <i>EMBO Molecular Medicine</i> , 2023, 15, .	3.3	8



#	ARTICLE	IF	CITATIONS
291	A Phase 1, Randomized, Double-Blinded, Placebo-Controlled and Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the Intranasal DelNS1-nCoV-RBD LAIV for COVID-19 in Healthy Adults. <i>Vaccines</i> , 2023, 11, 723.	2.1	3
292	The effect of SARS-CoV-2 variant on respiratory features and mortality. <i>Scientific Reports</i> , 2023, 13, .	1.6	5
293	Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: results from the COViK study. <i>Infection</i> , 2023, 51, 1093-1102.	2.3	3
294	Maternal and Perinatal Outcomes of SARS-CoV-2 and Variants in Pregnancy. <i>Maternal-Fetal Medicine</i> , 2023, 5, 104-114.	0.4	1
295	SARS-CoV-2 Variants Show Different Host Cell Proteome Profiles With Delayed Immune Response Activation in Omicron-Infected Cells. <i>Molecular and Cellular Proteomics</i> , 2023, 22, 100537.	2.5	2
296	More than a keyâ€”the pathological roles of SARS-CoV-2 spike protein in COVID-19 related cardiac injury. <i>Sports Medicine and Health Science</i> , 2023, , .	0.7	2
298	Evolution of Immune Evasion and Host Range Expansion by the SARS-CoV-2 B.1.1.529 (Omicron) Variant. <i>MBio</i> , 2023, 14, .	1.8	9
299	The evolution of SARS-CoV-2. <i>Nature Reviews Microbiology</i> , 2023, 21, 361-379.	13.6	239
300	SARS-CoV-2: Structure, Pathogenesis, and Diagnosis. , 2024, , 24-51.		0
302	Effectiveness of inactivated COVID-19 vaccines among older adults in Shanghai: retrospective cohort study. <i>Nature Communications</i> , 2023, 14, .	5.8	8
303	An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters. <i>Nature Communications</i> , 2023, 14, .	5.8	11
304	Case report: Severe pneumonia and pneumomediastinum in a previously robust adolescent caused by Omicron BA.5.2. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	1
305	Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants. <i>Cell Reports</i> , 2023, 42, 112443.	2.9	59
306	Virulence Profiles of Wild-Type, P.1 and Delta SARS-CoV-2 Variants in K18-hACE2 Transgenic Mice. <i>Viruses</i> , 2023, 15, 999.	1.5	3
307	Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses. <i>PLoS Pathogens</i> , 2023, 19, e1010870.	2.1	11
308	Rapid assembly of SARS-CoV-2 genomes reveals attenuation of the Omicron BA.1 variant through NSP6. <i>Nature Communications</i> , 2023, 14, .	5.8	15
311	Omicron variant evolution on vaccines and monoclonal antibodies. <i>Inflammopharmacology</i> , 2023, 31, 1779-1788.	1.9	9
319	Evolutionary characteristics of SARS-CoV-2 Omicron subvariants adapted to the host. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	3

#	ARTICLE	IF	CITATIONS
359	Chronicling the 3-year evolution of the COVID-19 pandemic: analysis of disease management, characteristics of major variants, and impacts on pathogenicity. Clinical and Experimental Medicine, 0, , .	1.9	0
371	Cooperative and structural relationships of the trimeric Spike with infectivity and antibody escape of the strains Delta (B.1.617.2) and Omicron (BA.2, BA.5, and BQ.1). Journal of Computer-Aided Molecular Design, 0, , .	1.3	0
412	Omicron: A SARS-CoV-2 Variant. , 0, , .		0
415	Host cyclophilin A facilitates SARS-CoV-2 infection by binding and stabilizing spike on virions. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	0
427	Pathogen evolution, prevention/control strategy and clinical features of COVID-19: experiences from China. Frontiers of Medicine, 2023, 17, 1030-1046.	1.5	0